The registration fee entitles delegates to the following:

  • Access to all scientific sessions
  • Catering: Morning tea, afternoon tea and lunch
  • Social Functions: Welcome Reception, EMCR networking event (for delegates that are EMCRs, this includes students).

Optional Extras:

Savour the coastal flavours of Fremantle at the conference dinner, held at the Bathers Beach House, where the ambiance is as inviting as the cuisine, offering a delightful dining experience complemented by stunning ocean views. Dinner tickets include canapés, 2 course meal and beverages.

We have arranged discounted tickets for an afternoon excursion to Rottnest Island on 29 October. Tickets include return ferry travel and the island admission fee. Once on the island you can explore at your leisure, go on a hike, enjoy a beverage or chat with a colleague, or come on a tour guided by one of our organising committee Perth locals.

Registration Rates (in Australian Dollars)

Please note that the prices below include GST at 10%. To be entitled to the early bird registration fee you must have registered and paid by 30 August 2024.

Registration TypeEarly Bird Rate (until 30 August 2024)Standard Rate (from 30 August 2024)Conference Dinner TicketRottnest Island Ticket
Student Member$500$600$55.00$55.00
Student Non-Member$600$700$82.50$60.00

Member rates apply for current financial members of AWTRS or MBSANZ.

Simon Cool
Director of the UQ Advanced Cell Therapy Manufacturing Initiative, and Director of Research in the School of Chemical Engineering at the University of Queensland

Professor Cool began his scientific career at the University of Queensland over 20 years ago. He received his BSc (hons) and PhD degrees from the University of Queensland, where he subsequently held a faculty position in the School of Biomedical Sciences. His areas of study have included age-related changes in the structure of bone and teeth and the extracellular matrix compartment of skeletal tissue that guide stem cell behaviour and wound repair. Professor Cool was invited to join the Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore in 2003 as a Principal Investigator. He then joined A*STAR’s Institute of Medical Biology (IMB) in 2008, shortly after its inception, to further his research in regenerative medicine, serving as Senior Principal Investigator of the Glycotherapeutics Group. In October 2020, Professor Cool re-joined the Institute of Molecular and Cell Biology (IMCB) as a Research Director, Glycotherapeutics, where he focused on developing novel glycosaminoglycan biomolecules that enhance wound repair and control adult human mesenchymal stem cell activity. Professor Cool returned to the University of Queensland, joining the School of Chemical Engineering in January 2022.

Amanda Kijas
Australian Institute for Bioengineering and Nanotechnology, University of Queensland, Australia

Dr Amanda W. Kijas is a multidisciplinary researcher based at The University of Queensland, leading a new wound healing research program focused on interrogating the underlying science and how we can leverage this to develop innovative new approaches to wound healing products. Repurposing nature’s innovation to instruct better wound healing outcomes from the first stage of bleeding control to driving ordered and timely wound regeneration. With a focus on instructing cellular responses through the biophysical cues that act in synergy with the biochemical microenvironment to modulate these dynamic spatiotemporal cellular responses.

Kendelle Murphy
Garvan Institute of Medical Research, Australia

Dr Kendelle Murphy is a Senior Research Officer in the Cancer Invasion and Metastasis Laboratory at the Garvan Institute of Medical Research. Cancer develops in a complex three-dimensional environment, where tumour cell communication with the surrounding stroma governs cancer cell behaviour. Dr Murphy uses novel state-of-the-art intravital (in vivo, ACRF INCITe Centre) imaging approaches to provide new insights into how cells behave in a physiologically relevant environment, thereby improving our understanding of disease progression, drug delivery and efficacy. Pancreatic Ductal Adenocarcinoma (PDAC) is a highly lethal disease with few treatment options. Multimodal chemotherapy regimens including gemcitabine/Abraxane and FOLFIRINOX are the current standard-of-care in the clinic, however these have limited benefits to extend survival. Focal Adhesion Kinase (FAK) is known to modulate bi-directional communication between the tumour and surrounding ECM driving disease, influencing disease progression, therapy response and the development of pro-tumorigenic fibrosis.
As a CINSW (ECR) Fellow Dr Murphy conducts research has a clear focus on clinical translation. Importantly this research led to the establishment of a Phase II clinical trial (Amplia Therapeutics Ltd, ACCENT Trial, Q3 2022), highlighting the translational and collaborative capacity of her work.

Kylie Sandy-Hodgetts
Centre for Molecular Medicine & Innovative Therapeutics, Murdoch University, Australia

Kylie is Associate Professor, Centre for Molecular Medicine & Innovative Therapeutics, Murdoch University and Honorary Senior Lecturer, School of Medicine, Cardiff University. She is Founder and President of a not-for-profit association, the International Surgical Wound Complications Advisory Panel (ISWCAP). ISWCAP’s vision is to generate awareness of surgical wound complications and improve outcomes for patients through early detection, and prevention via education and research with an international panel of experts. Kylie is a Research Scientist and Chief Investigator of several clinical trials ranging from Phase 1 first in human studies to phase 3-4 comparative effectiveness trials. Kylie’s research focuses upon early identification, prevention and management of surgical wound complications including surgical site infection (SSI) and surgical wound dehiscence (SWD). Kylie has Chaired and co-authored over 5 international clinical consensus documents, first authored over 25 original research papers and chaired the ISWCAP Best Practice Statement on the early identification and prevention of surgical wound complications. She is a reviewer for peer reviewed journals and sits on several journal editorial boards.
She is a Past Chair of the Board of Wounds Australia and has served on several national and international boards including the World Union of Wound Healing Societies (WUWHS) Executive Board as Recorder and the Scientific and Ethics Committee. Kylie Chaired the Australian National Steering Committee Surgical Wounds Panel and Wound Research Directory for the Australian Health Research Alliance National Wound Care Initiative (2020-2023). She was acknowledged internationally for her contribution to the field of surgical site infection prevention as the 2021 Winner of the Journal of Wound Care World Union Innovation in Surgical Site Infection Award.

Fiona Wood
UWA Medical School, University of Western Australia, Australia

Winthrop Professor Fiona Wood University of Western Australia is a Plastic & Reconstructive Surgeon specialising in the field of burn care, trauma, and scar reconstruction. As Director of the WA Burns Service of Western Australia since 1991 she is consultant surgeon at both the South Metropolitan Heath Service, Fiona Stanley Hospital and the Child and Adolescent Health Service, Perth Children’s Hospital. As director of burns injury research unit she leads an interdisciplinary team with broad collaboration focused on translation to improve clinical outcomes. She sits on the national science and technology council and was Australian of the year in 2005.

Khoon Lim
School of Medical Sciences, University of Sydney, Australia

Khoon is a biomedical engineer with specialization in polymer chemistry. He completed a concurrent degree – Bachelors (Hons 1) in Chemical Engineering and Masters in Biomedical Engineering, followed by a PhD in Biomedical Engineering (graduated 2014) from the University of New South Wales. He then went to join the Department of Orthopedic Surgery and Musculoskeletal Medicine at the University of Otago Christchurch in New Zealand for a postdoctoral fellowship, where he established the Light Activated Biomaterials (LAB) research group in 2019. In 2022, he joined the University of Sydney.
His research focus is on adopting a class of polymers known as hydrogels as tissue engineering matrices for a variety of applications. His has developed a number of research technology platforms, primarily using photo-polymerizable hydrogel bioinks for 3D bioprinting of functional tissues and also delivery of bioactive molecules to promote tissue regeneration. He has successfully raised a total of >$8M research grant funding ($6.5M as lead CI). He has been awarded a number of New Zealand’s most prestigious grants and fellowships, including the MARSDEN Fast Start Grant and Rutherford Discovery Fellowship from the Royal Society of New Zealand, as well as the Emerging Researcher First Grant, Sir Charles Hercus Health Research Fellowship and Project Grant from the Health Research Council of New Zealand. Since his move to Australia, he has been successful in attracting funding in a number of prestigious schemes, including the NSW Health Cardiovascular Elite Grant and the Australian Research Council Future Fellowship.

Ferry Melchels
Future Industries Institute, University of South Australia, Australia

Ferry Melchels is the research professor of Biomaterials and Tissue Engineering at the Future Industries Institute at UniSA (Mawson Lakes campus). His main interests lie in polymeric biomaterials for 3D printing, tissue engineering, and drug and vaccine delivery. His work has been published in leading journals, attracting over 16,000 citations. He is a recipient of the Patrick Neill Medal for Early Career Researchers in the Life Sciences from the Royal Society of Edinburgh, and the Mid-Career Investigator Award from the International Society for Biofabrication.
Ferry holds an MSc (2005) in chemical engineering and PhD (2010) in biomaterials from the University of Twente (The Netherlands). He was a Marie Curie post-doctoral fellow between two of the pioneering institutes in Biofabrication; Queensland University of Technology (Brisbane, Australia) and University Medical Center Utrecht (The Netherlands) and held his first PI position at Heriot-Watt University in Edinburgh (UK) from 2015-2023. Besides home brewing the best beers on the weekend, his future aim is to continue advancing materials-based technology platforms for biomedical applications.

Clair Baldock
Professor of Biochemistry at the Manchester Cell-Matrix Centre, University of Manchester, UK

Clair Baldock is a Professor of Biochemistry at the University of Manchester and Group Leader in the Manchester Cell-Matrix Centre. After a PhD in X-ray crystallography at the University of Sheffield, Clair was awarded a Royal Society Study Visit to the University of Auckland to develop further skills in protein biochemistry and molecular biology in Professor Ted Baker’s group. Following this, Clair completed postdoctoral training in the group of Professor Cay Kielty at the University of Manchester and was subsequently awarded a Royal Society Olga Kennard Research Fellowship in 2001 to establish her independent research group with focus on the structure and function of cell-matrix assemblies and complexes, in particular elastic fibre proteins fibrillin and tropoelastin. In 2007, Clair was awarded a tenured position at the University of Manchester where her research group continues to focus on the extracellular regulation of growth factor signalling using a combination of structural, cell biological and biochemical approaches. Recently, her team has determined the structure of fibrillin microfibrils from mammalian tissue using cryo-electron microscopy to reveal the consequence of pathogenic mutations on latent TGFβ binding.

Jennifer Young
Mechanobiology Institute, National University of Singapore, Singapore

Jennifer Young was trained as a biomedical engineer at the University of California, San Diego. During her Ph.D. with Prof. Adam Engler, she studied the role of mechanics in cardiac development, and created a hydrogel system capable of mimicking dynamic tissue properties in vitro. Inspired by the role of extracellular matrix (ECM) in dictating cell behaviour and fate, she joined the Cellular Biophysics group of Prof. Joachim Spatz at the Max Planck Institute for Medical Research (Heidelberg, Germany) to study the contribution of nanoscale ECM cues to cellular function. There, she discovered that variations in nanoscale ligand presentation alone affect chemoresistance in breast cancer cells, which has great implications in cancer treatment strategies. Currently she is at the Mechanobiology Institute and Biomedical Engineering Department at the National University of Singapore where her work focuses on identifying and mimicking micro-to-nanoscale matrix properties and unravelling their contributions to cellular behaviour in a diverse set of biological environments.

Andrew Holle
Mechanobiology Institute, National University of Singapore, Singapore

Andrew Holle received a Bachelor of Science, Engineering (B.S.E) from Arizona State University, where he worked in labs of Dr. Christine Pauken and Dr. Deirdre Meldrum. He then received his Ph.D. at the University of California, San Diego, where he worked in Dr. Adam Engler’s Stem Cell Biology and Bioengineering group. There, he identified the mechanosensitive role of the focal adhesion protein vinculin in substrate stiffness-induced stem cell differentiation. Looking to explore the commonalities between stem cell and cancer mechanobiology, he then joined Prof. Joachim Spatz’s Cellular Biophysics group at the Max Planck Institute for Medical Research (Stuttgart, Germany). There, he used photolithography and microfluidics to build microchannel assays to better characterize cancer cell invasion and migration in confinement. His Confinement Mechanobiology lab at the Mechanobiology Institute and in the NUS Biomedical Engineering department focuses on the role of confinement in mechanobiology, with an emphasis on novel strategies for controlling stem cell differentiation.

Alexander Nyström
Department of Dermatology, Medical Center – University of Freiburg, Freiburg, Germany

Dr Nyström’s main focus is the extracellular matrix and the dermal microenvironment in homeostasis and as initiator and driver of chronic wounds, fibrosis and cancer. To understand the multifaceted roles of the extracellular matrix, its specific components and their deficiencies play in these processes, it is necessary to go beyond the skin. Dr Nyström has an interest in the monogenetic skin blistering disorder dystrophic epidermolysis bullosa (DEB) (caused by deficiency of type VII collagen). People with DEB develop chronic wounds, progressive soft tissue fibrosis and aggressive SCCs at an early age. My group uses the disease as a model to delineate mechanisms for orphan genetic and common acquired disorders. Consequently, part of our research is focused on development of causative and evidence-based symptom-relief therapies for DEB. The aim is that some of these therapies can also be applied to common acquired wound healing pathologies.
Dr Nyström studied biochemistry and molecular biology at Lund University, Sweden and obtained a doctoral degree from the same university for studies on laminins in health and acquired and genetic diseases in the laboratory of the late Dr. Peter Ekblom. After postdoctoral work on proteoglycans in the laboratory of Dr. Renato Iozzo at the Thomas Jefferson University in Philadelphia, following Dr Nyström moved to the laboratory of Dr. Bruckner-Tuderman Freiburg, Germany to focus his research on skin biology. Since 2013 Alexander has his own independent research group at the Department of Dermatology, Medical Center – University of Freiburg, Freiburg Germany.

Claudia Loebel
Assistant Professor of Materials Science & Engineering at the University of Michigan, USA

Claudia Loebel, M.D. Ph.D., is an Assistant Professor of Materials Science & Engineering and a Biological Sciences Scholar at the University of Michigan, US. She obtained her MD (2011) at the Martin-Luther University Halle-Wittenberg in Germany and PhD (2016) at ETH Zurich (Switzerland) and completed a postdoctoral fellowship in the laboratory of Professor Jason Burdick at the University of Pennsylvania. Her research involves the development of metabolic labelling approached and biomaterial platforms to characterize and uncover the role of nascent matrix microenvironments on cell and tissue function. The applications of this research range from guiding lung alveolar stem/progenitor cell fate through material cues to developing engineered platforms for tissue repair and therapeutic treatment. Claudia Loebel is currently serving as an Associate Editor of the Wiley Journal of Biomedical Materials Research Part A (JBMRA). She was awarded the 2023 David and Lucile Packard Foundation Fellowship for her work on cell-matrix interactions, and the Pathway to Independence Award (K99/R00) through the National Heart, Lung, and Blood Institute at NIH and the Innovator Award through the American Lung Association to probe mechanisms of alveolar epithelial cell dysfunction.

Yuval Rinkevich
Director of the Helmholtz Institute of Regenerative Biology and Medicine at the Helmholtz Center, Munich, Germany

Dr. Rinkevich has been working at the cutting edge of our understanding of tissue/organ repair and regeneration for the last 20 years. The scientific focus of the Rinkevich lab lies in identifying principles of tissue/organ repair and regeneration, and developing a knowledge foundation for therapeutic strategies in clinical use. His lab explores the stem cells, cellular lineages and mechanisms by which tissues/organs repair and regenerate following injury.

His passion for healing responses and tissue rejuvenation can be traced throughout his career track, obtaining his PhD degree from the Technion-Israel Institute of Technology, where he studied whole body regeneration from single blood vessels in Protochordates. Dr Rinkevich moved to Stanford University in the US to join the renowned immunology lab of Prof. Irving L. Weissman, where he explored the cellular lineages and stem cells in mammalian tissue repair and regeneration. His work at Stanford projected Dr Rinkevich into the forefront of the tissue repair field for his pioneering work uncovering the role of fibroblast lineages in the transition from scarless to scar forming tissue responses.

Today Dr Rinkevich is the Director of the Helmholtz Institute of Regenerative Biology and Medicine at the Helmholtz Center, Munich, Germany. His lab continues to push forward our understanding of tissue/organ repair and regeneration. His latest work describing the fascia in tissue fibrosis in multiple organ systems is reinventing the way we look at tissue repair and regeneration, opening our minds to a revolution in antifibrotic therapy and the potential to prevent and potentially resolve fibrotic disease.

Hello world.

This is a sample box, with some sample content in it.

TEMTIA X Updates

Enter your details below to learn about the latest developments as we prepare for TEMTIA X in November.